October 3, 2016 – Montreal, QC, Toronto and Ottawa, ON ─ KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co-developing since 2015.
The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom-engineered therapeutic developed at NRC.
The team received a $1.5M grant from the Weston Brain Institute to enable trials of the treatment in humans, which will be led by the Douglas Research Institute Centre, affiliated with McGill University. The first patients, who are Canadians with Alzheimer’s disease, are expected to be recruited in 2017. The clinical trial will be conducted at the Montreal Neurological Institute and Hospital (McGill University). The Centre for Imaging Technology Commercialization (CIMTEC) will provide brain imaging services.
For the full English Press Release click here
For the full French Press Release click here